Three biotechs reported devastating clinical trial failures this month. Here are the important takeaways.
News & Analysis: Prothena
Shares plunge after the company announces that it is halting development of its lead pipeline candidate. Here's what investors need to know.
The company's landed a new collaboration partner and a new investor.
A sudden executive departure leaves Prothena's shareholders worried.
An advancing pipeline of drugs targeting important diseases could provide market-moving news over the coming year.
Our Motley Fool contributors like these high-risk stocks for the long term, and perhaps you should, too.
Interested in stocks with huge growth potential? These three stocks hold promise for big gains in the years ahead.
These big biotech winners more than tripled in value this year.
These companies are developing new treatments for Alzheimer's disease and Parkinson's disease that could bring in billions if they succeed.
Early stage trial results for Prothena's PRX002 sent shares higher last month.